Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis

Abstract Background Pleural effusion is a common clinical problem in patients with cancer. We aimed to summarize all the known prognostic indicators of malignant pleural effusion. Methods We did a systematic review and meta-analysis with a systematic literature search. All prospective or retrospective cohort studies that estimated the prognostic factors of malignant pleural effusion were enrolled. Mantel–Haenszel method was used to calculate the pooled hazard ratio (HR) and 95% confidence interval (CI). Results Eventually, we identified 82 studies with a total of 10,748 patients that met our inclusion criteria. The LENT score showed a good prognostic value (HR 1.97, 95% CI 1.67–2.31) so did the LENT score item. In addition, clinical parameters like stage (HR 1.68, 95% CI 1.25–2.25), distant metastasis (HR 1.62, 95% CI 1.38–1.89), EGFR mutation (HR 0.65, 95% CI 0.56–0.74), serum biological parameters like hemoglobin (HR 1.56, 95% CI 1.17–2.06), albumin (HR 1.71, 95% CI 1.25–2.34), C-reaction protein (HR 1.84, 95% CI 1.49–2.29), VEGF (HR 1.70, 95% CI 1.18–2.43) and pleural effusion biological parameters like PH (HR 1.95, 95% CI 1.46–2.60), glucose (HR 1.75, 95% CI 1.18–2.61), VEGF (HR 1.99, 95% CI 1.67–2.37), and survivin (HR 2.90, 95% CI 1.17–7.20) are also prognostic factors for malignant pleural effusion. Conclusions For malignant pleural effusion, LENT score and its items are valuable prognostic biomarkers, so do the clinical parameters like stage, distant metastasis, EGFR mutation, the serum biological parameters like hemoglobin, albumin, C-reaction protein, VEGF and the pleural effusion biological parameters like PH, glucose, VEGF and survivin.